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Introduction.	
Glioma	Modelling	Project	is	a	tool	that	could	potentially	aid	any	neuropathologist	across	
the	world	to	diagnose	brain	tumors.	According	to	the	World	Health	Organization	(WHO),	
they’re	around	200	types	of	brain	and	central	nervous	system	tumors.	Gender,	age,	ki-67,	
general	and	specific	sites	are	the	five	parameters	that	we	selected	in	order	to	predict	brain	
tumors	with	an	accuracy	of	sixty	percent.	This	originally	created	with	the	idea	of	saving	a	
patient’s	money	in	medical	proves.	Additionally,	there	are	some	countries	that	do	not	have	
access	to	the	same	technology	or	laboratories	that,	for	example,	the	United	States	has.	
Therefore,	Glioma	Modelling	Project	could	simplify	and	avoid	additive	expenses	of	some	
laboratory	processes	that	some	hospitals	do	not	have.		
	 Tumors	that	arise	in	the	brain	usually	involves	brain	tissue,	brain	nerve	endings,	brain	
membranes,	skull	bones	or	skull	muscles	and	are	called	primary	brain	tumors.	If	they	extend	to	
other	organs	of	the	body,	they	are	classified	as	metastatic	or	secondary	cerebral	tumors.		
Within	primary	brain	tumors,	they	can	be	distinguished	between	two	categories	based	on	the	
microscopic	appearance:	benign	and	malignant.		A	benign	tumor	is	a	tumor	that	will	not	spread	
through	the	body	or	invade	its	surrounding	tissue.	However,	a	malignant	tumor	could	
potentially	invade	the	surrounding	tissue	and	spread	through	the	body.	In	addition,	primary	
brain	tumors	can	be	categorized	as	glial	(if	they	are	composed	of	glial	cells)	or	non-glial	(if	they	
are	developed	in	brain	structures	that	include	nerves,	blood	vessels	as	well	as	glands).	
Metastatic	brain	tumors,	or	secondary	cerebral	tumors,	do	not	arise	in	the	brain	but	in	other	
body	parts	and	migrate	to	the	brain,	most	commonly	through	the	bloodstream	(AANS).		
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	 There	are	different	types	of	benign	brain	tumors	such	as	Chordomas,	
Craniopharyngiomas,	Gangliocytomas,	Glomus	jugulare,	Meningiomas,	Pineocytomas,	Pituitary	
adenomas	and	Schwannomas.	Gliomas,	Astrocytomas,	Ependymomas,	Glioblastoma	
multiforme,	Medulloblastoma	and	Oligodendriogliomas	are	all	malignant	brain	tumors	found,	
with	gliomas	being	the	most	common.	All	of	them	arise	from	the	glia,	which	are	supporting	cells	
that	are	subdivided	into	astrocytes.	These	star-shaped	supporting	cells	are	part	of	the	
supportive	tissue	of	the	brain.	Ependymal	cells	are	thin	neuroepithelial	lining	of	the	ventricular	
system	of	the	brain	and	the	central	canal	of	the	spinal	cord,	with	oligodendroglial	cells	
providing	support	and	insulation	to	axons	in	the	CNS	(AANS).		
The	WHO	divides	brain	tumors	into	four	categories	according	to	their	growth	tendencies	
and	data	on	histomorphology	and	molecular	status.	Tumors	that	grow	slowly	are	classified	as	
low-grade	and	can	be	grades	I	or	II,	whereas	ones	that	grow	more	aggressively	are	always	
classified	as	III	or	IV	high-grade	tumors.	However,	it	is	very	important	to	understand	that	all	
tumors	are	independent	from	the	grade	they	are	classified	as,	with	all	of	them	being	life	
threatening	(AANS).	
Grade	I	tumors	are	usually	the	least	malignant,	typically	curable	via	non-infiltrative	
surgery,	and	have	long-term	survival	rates	as	they	are	slow	growing.	Pilocytic	astrocytoma,	
Craniopharyngioma,	Glangliocytoma	and	Ganglioglioma	are	examples	of	this	classification.	
Diffuse	Astrocytoma,	Pineocytoma,	and	pure	oligodendroglioma	are	Grade	II	tumors.	They’re	
relatively	slow	growing,	somewhat	infiltrative	surgery	and	they	may	recur	as	a	higher	grade.	
Grade	III	tumors	are	both	malignant	and	infiltrative	and	they	usually	tend	to	recur	as	a	higher	
grade.	Anaplastic	astrocytoma,	Anaplastic	ependymoma	and	Anaplastic	oligodendroglioma	are	
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found	(AANS)	in	this	category.	Grade	IV	tumors	are	the	most	malignant.	They	grow	very	
aggressively,	are	widely	infiltrative,	and	have	a	rapid	recurrence	as	well	as	being	prone	to	
necrosis.	Glioblastoma	multiforme,	Pineoblastoma,	Medulloblastoma	and	Ependymoblastoma	
are	the	types	of	tumors	that	fall	within	this	category.	Figure	1	below	shows	these	four	
categories.	
Figure	1.	WHO	Scheme	explains	how	the	tumors	are	being	classified	
In	2016,	the	WHO	restructured	brain	tumor	classification	by	incorporating	new	entities	
that	included	histology	and	molecular	features	in	their	nomenclature.	Examples	of	this	are	
Glioblastoma	IDH-wildtype	and	glioblastoma	with	IDH-mutant;	diffuse	midline	glioma	H3	K27M-
mutant;	RELA	fusion-positive	ependymoma;	medulloblastoma	with	WNT-activated	and	
medulloblastoma	SHH-activated;	as	well	as	embryonal	tumor	with	multilayered	rosettes,	and	
C19MC-altered.	The	WHO	also	deleted	some	entities	that	are	no	longer	biologically	relevant.				
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	 For	diagnoses	closer	to	0%	malignance,	the	expected	molecular	features	are	IDH	
mutation,	1p/19q	codeletion	and	TP53	mutation	(Pisapia,	2017).	IDH1		is	a	gene	that	encodes	a	
metabolic	enzyme	named	isocitrate	dehydrogenase	1.	This	enzyme	catalyzes	the	conversion	of	
isocitrate	to	alpha-ketoglutarate.	The	mutation	of	this	gene	predicts	longer	survival.	Methylated	
MGMT	is	an	inactive	gene	that	also	predicts	a	longer	length	of	survival.	1p19q	codeletion	is	the	
combination	of	a	complete	loss	of	the	short	arm	chromosome	1	and	the	long	arm	of	
chromosome	19.	This	marker	usually	encodes	for	a	better	prognosis	(Muzio	et	al.).	EGFR	
mutation	has	a	high	level	of	cytokines	that	usually	activates	gp130		and	leads	to	cell	
proliferation	(Olar	et	al.,	2014).	The	features	that	distinguish	glioblastomas	from	other	
diagnoses	are	the	appearance	of	dead	cells	or	necrosis	as	well	as	the	increase	of	blood	vessel	
growth	around	the	tumor	(ABTA).	Glioblastomas	can	be	divided	into:	Glioblastoma	IDH-
wildtype	and	IDH-mutant.	
	 Glioblastoma	IDH-wiltype,	are	most	commonly	found	within	the	temporal	lobe	(in	31%	
of	the	cases),	the	parietal	lobe	(in	24%)	and	in	the	frontal	lobe	(in	23%)	(WHO,	2016).	
Predominantly	found	within	patients	around	55	years	of	age	(ABTA),	this	type	of	tumor	will	
most	likely	include	positive	ATRX	as	well	as	IDH1	and	p53	(Pisapia,	2017).	
	 For	glioblastoma	IDH-mutant,	it	is	predominetly	found	within	the	frontal	lobe	(WHO,	
2016).	The	IDH-mutant	is	usually	found	in	patients	around	45	years	old	(ABTA).	This	tumor	is	
positive	for	IDH1	mutation	as	well	as	ATRX	(indicating	intact	expression)	and	commonly	shows	a	
wild-type	pattern	for	p53	expression	(Pisapia,	2017).	
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	 In	order	to	compare	and	constrast	how	molecular	and	clinical	features	differ	within	
tumors,	a	subtype	of	oligodendroglioma,	meningiomas	and	astrocytic	tumors	will	be	explored	
in	detail.	
	In	oligodendroglioma	IDH-mutant	and	1p/19q-codeleted	the	most	common	location,	
accounting	for	more	than	50%,	is	the	frontal	lobe	followed	by	the	temporal,	parietal	and	
occipital,	respectively.	The	involvement	of	more	than	one	cerebral	lobe	is	not	common	(WHO,	
2016).	The	common	age	range	for	this	diagnosis	is	between	35	to	44	years,	and	is	rare	when	
found	in	patients	younger	than	16	(Martinez-Larger	et	all,	2019).	IDH1	as	well	as	1p/19q	co-
deletion	is	found	within	this	tumor	type.	
Pleomorphic	xanthoastrocytoma	is	often	found	within	the	supratentorial	region,	most	
commonly	in	the	frontal	lobe	(WHO,	2016).	The	mean	age	is	aroud	18	years.	Necrosis	is	usually	
not	presented	as	well	as	IDH	mutation.	BRAF	V600E	is	often	mutated.	The	combination	of	BRAF	
V600E	mutation	with	an	absence	of	IDH	mutation	supports	the	pleomorphic	
xanthoastrocytoma	diagnosis	(WHO,	2016).		
The	majority	of	meningiomas	arise	in	intracranial,	intraspinal	or	obital	locations	(WHO,	
2016).	This	tumor	it	is	not	aplicable	for	1p/19q	neither	IDH1	and	IDH2	mutations	(WHO,	2016).		
Machine	learning	is	an	application	of	automatic	artificial	intelligence	that	has	the	
capacity	to	automatically	learn	and	improve	from	experience	without	being	programmed	by	
their	provided	systems.	It	is	focused	on	the	progress	of	computer	programs	and	data	access	
(Expert	System,	2019).	There	are	two	major	types	of	machine	learning	algorithms:	supervised	
machine	learning	algorithms	and	unsupervised	machine	learning	algorithms:	
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	 Supervised	machine	learning	algorithms	can	predict	future	events	based	on	applying	
what	they	already	know	from	the	past	to	new	data	using	tagged	examples.	From	a	known	data	
training	dataset,	supervised	machine	learning	creates	a	certain	function	that	make	predictions	
about	the	possible	output	values.	This,	can	also	contrast	the	calculated	output	with	the	correct	
one	in	order	to	find	errors	that	could	modify	the	model	(Expert	System,	2019).	
	 Unsupervised	machine	learning	algorithms	are	used	when	there	is	no	necessity	to	
classify	or	label	certain	information.	Thus,	it	can	infer	a	function	to	describe	a	hidden	structure	
from	no	labeled	data.	The	main	advantage	of	this	algorithm	is	that	it	examines	the	given	data	
and	can	show	inferences	from	datasets	in	order	to	depict	hidden	structures	from	unlabeled	
data.	Also,	this	algorithm	usually	does	not	calculate	the	right	output	(Expert	System,	2019).	
	 Confusion	matrix	or	error	matrix	solves	the	problem	of	statistical	classification.	It	is	the	
total	results	of	predictions	of	a	determined	classification	problem.	The	main	point	of	the	
confusion	matrix,	is	the	summation	of	the	correct	and	incorrect	predictions	with	count	values	
and	broken	down	by	each	class	showing	which	parts	of	the	model	are	causing	that	confusion,	
while	assessing	what	type	of	errors	are	being	made	(GeeksforGeeks,	2018).	
	 Decision	trees	were	the	algorithms	used	to	predict	the	possibilities	of	diagnosis	at	the	
highest	accuracy.	A	decision	tree	can	complete	classification	as	well	as	regression	tasks	of	
complex	datasets.	The	algorithms	are	used	in	order	to	construct	our	model	were	Random	
Forest,	Boruta,	XGBoost	and	C5.0.	
	
	Methods.	
1. “La	Tabla”	
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In	order	to	organize	the	different	tumor	types,	the	most	updated	version	of	the	WHO	
Classification	of	Tumors	of	the	Central	Nervous	System	in	2016,	was	taken	to	set	up	a	Microsoft	
Excel	table	called	“La	Tabla”	that	contained	all	the	tumor	types	in	the	y	axis.	All	the	tumor	types	
were	carefully	distributed	according	to	specific	age	of	diagnosis	onset,	e.g.	Figure	2.	
	
Figure	2.	Distribution	of	tumor	types	based	on	mean	age	of	diagnosis.	
	
The	x	axis	is	composed	of	the	tumor	type,	cell	type,	epidemiological	features	linked	to	
frequency,	mean	age,	SD	of	mean	age,	median	age,	SD	of	median	age,	range	age,	gender	ratio,	
anatomical	sites,	global	cellularity,	pattern	of	growth,	architectural	pattern,	type	of	cells	
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according	to	frequency,	nuclear	pleomorphism,	additional	features,	referred	to	Ann-Mayo	
classification	immunohistochemistry,	molecular	data	and	references.		
	 Some	of	the	x-axis	labels	are	subdivided	into	different	categories:	Global	cellularity	is	
subdivided	between	low	cellularity,	medium	cellularity	and	high	cellularity.	Pattern	of	growth	is	
split	in	to	infiltrative	diffuse	and	solid	with	infiltration.	Architectural	pattern	is	divided	in	to	
nodular	(nests),	solid	discohesive,	cords	or	columns,	chicken-wire,	pseudopapillary,	
mycrocystic,	myxoid	areas,	perivascular	pseudorosettes,	multilayered	rosettes,	storiform	and	
desmoplasia.	Type	of	cells	according	to	frequency	is	subcategorized	in	to	astrocytic	like	
(fibrillary,	gemistocytic,	piloid),	resemble	subependymal	glia	(including	physal-cells),	rounded	
cells	with	clear	halo	(including	neurocytic	cells),	gigant	multinucleated	cells,	rabdohid	cells	(cells	
with	large	eosinophilic	cytoplasm,	with	rounded	nuclei	with	prominent	nucleoli),	ganglion	cells	
(large	cells,	with	only	one	nuclei,	usually	euchromatic),	lipidized	cells	(includes	multivacuolated	
and	focal	accumulation	of	lipid-laiden	cells),	small	rounded	blue	cells	and	epitheloid	cells.	Low,	
medium	and	high	nuclear	pleomorphism	fall	within	the	nuclear	pleomorphism’s	category.	In	
some	additional	features	dysplastic	neurons	(neurons	that	look	like	mature	neurons	but	are	
binucleated),	rosental	fibers,	eosinophil	granular	bodies,	perivascular	lymphocytes	as	well	as	
calcifications	are	found.	Referred	to	Ann-Mayo	classification	is	divided	in	to,	mitosis,	
endothelial	proliferation	and	necrosis.	Immunohistochemistry	is	subdivided	between	GFAP,	
ATRX	loos,	p53,	IDH1	R123H,	INI1	(loss	stain)	and	ki67.	Finally,	molecular	data	is	divided	in	to	
the	presence	or	absence	of	IDH1	and	IDH2	mutation,	EGFR	amplification,	MGMT	promoter	
methylation,	BRAF	V600E	mutation,	1p/19q	codelection	FISH	and	1p/19q	codelection	LOH.	
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	 The	majority	of	the	information	was	found	within	the	2007	and	2016	version	of	the	
WHO	Classification	of	Tumours	of	the	Central	Nervous	System.	The	rest	of	the	information	was	
reached	from	scholar	articles	as	well	as	neurophatology	and	neuro-oncology	literature.		
Tables	1	and	2	include	the	information	that	we	got	based	on	literature	with	the	
corresponding	references	of	the	two	of	the	five	parameters	selected	for	the	shiny	app.	
Table	1.	Feature	Age	extracted	from	“La	Tabla”	with	its	corresponding	references.	
WHO	Tumor	Type	 Age	 Citation	
Anaplastic	Astrocytoma,	WHO	grade	III,	IDH-mutated						 57.25838	 [74]	
	Anaplastic	Astrocytoma,	WHO	grade	III,	IDH-wild	type		 56.17389	 [74]	
Anaplastic	Ependymoma,	Posterior	Fossa	A,	WHO	grade	III	 3.470269	 [74]	
	Anaplastic	Ependymoma,	Posterior	Fossa	B,	WHO	grade	III	 30.15434	 [74]	
Anaplastic	Ependymoma,	Spine,	WHO	grade	III	 42.3617	 [74]	
	Anaplastic	Ependymoma,	Supratentorial-RELA,	WHO	grade	III	 8.871502	 [74]	
	Anaplastic	Ependymoma,	Supratentorial-YAP,	WHO	grade	III	 4.023892	 [74]	
Anaplastic	Ganglioglioma																			 32.9504	 [74]	
	Anaplastic	Oligodendroglioma																							 52.94719	 [74]	
Anaplastic	Pleomorphic	Xanthoastrocytoma																	 25.40757	 	[22],	[44]	
Angiocentric	Glioma																		 20.1175	 [57]	
Astroblastoma																																								 20.91529	 [75]	
Astrocytoma,	WHO	grade	II,	IDH-Mutated																 37.82914	 [74]	
Astrocytoma,	WHO	grade	II,	IDH-wild	type							 38.05708	 [74]	
Atypical	Choroid	Plexus	Papilloma,	WHO	grade	II				 37.63072	 [75]	
Atypical	Rhabdoid	Tumour											 8.161617	 [38],	[74]	
Central	Neurocytoma																											 29.80568	 [38],	[75]	
Cerebellar	Liponeurocytoma,	WHO	grade	II														 49.97034	 [75]	
Choroid	Glioma	Of	The	Third	Ventricle										 36.30717	 [38],	[75]	
Choroid	Plexus	Carcinoma																											 24.94233	 [38]	
Choroid	Plexus	Papilloma										 27.08243	 [38]	
Desmoplastic	Infantile	Astrocytoma,	WHO	grade	I									 1.605161	 [125]	
Desmoplastic	Infantile	Ganglioglioma						 4.188498	 [125]	
Diffuse	Leptomeningeal	Glioneuronal	Tumour			 12.22865	 [75]	
Diffuse	Midline	Glioma,	WHO	grade	IV											 14.7292	 [75]	
Diffuse	Oligodendroglioma,	WHO	grade	II							 46.10527	 [75]	
Dysembryoplastic	Neuroepithelial	Tumor							 10.91598	 [75]	
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Dysplastic	Cerebellar	Gangliocytoma,	WHO	grade	I							 38.08859	 [75]	
Ependymoma,	Posterior	Fossa	A,	WHO	grade	II		 4.589818	 [75]	
Ependymoma,	Posterior	Fossa	B,	WHO	grade	II					 30.41535	 [75]	
Ependymoma,	Spine,	WHO	grade	II							 42.31803	 [75]	
Ependymoma,	Supratentorial-YAP,	WHO	grade	II		 4.119103	 [75]	
Ependymoma,	Supratentorial,	RELA,	WHO	grade	II			 8.636612	 [75]	
Extraventricular	Neurocytoma							 40.17644	 [75]	
Gangliocytoma,	WHO	grade	I	 31.83199	 [38]	
Ganglioglioma										 22.12451	 [75]	
Glioblastoma,	IDH-mutated																													 50.51262	 [75]	
Glioblastoma,	IDH-wild	type											 60.90557	 [75]	
Medulloblastoma,	non-WNT/non-SHH,	WHO	grade	IV	 25.58433	 [75]	
Medulloblastoma,	SHH	Class,	WHO	grade	IV						 15.56225	 [75]	
Medulloblastoma,	WNT	Group,	WHO	grade	IV							 13.41433	 [75]	
Meningioma,WHO	grade	I	 60.61425	 [75]	
Myxopapillary	Ependymoma							 36.30467	 [27]	
Paraganglioma																												 38.12739	 [75]	
Pilocytic	Astrocytoma													 22.16353	 [38],	[74]	
Pilomyxoid	Astrocytoma																 1.614674	 [38],	[83]	
Pleomorphic	Xanthoastrocytoma,	WHO	grade	II	 29.37606	 [38],	[100]	
Rosette-forming	Glioneuronal	Tumors,	WHO	grade	I	 27.18834	 [129]	
Schwannoma,	WHO	grade	I	 58.32085	 [75]	
Solitary	Fibrous	Tumour/Hemangiopericytoma	Grade	I	 43.00789	 [75]	
Subependymal	Giant	Cell	Astrocytoma,	WHO	grade	I	 14.20517	 [92]	
Subependymoma	 37.37762	 [38],	[61]	
Table	2.	Feature	Ki-67	extracted	from	“La	Tabla”	with	its	corresponding	references.	
WHO	Tumor	Type	 Ki-67	 Citation	
Anaplastic	Astrocytoma,	WHO	grade	III,	IDH-mutated						 26.40252	 [123]	
	Anaplastic	Astrocytoma,	WHO	grade	III,	IDH-wild	type		 26.33504	 [123]	
Anaplastic	Ependymoma,	Posterior	Fossa	A,	WHO	grade	III	 12.69119	 [75]	
	Anaplastic	Ependymoma,	Posterior	Fossa	B,	WHO	grade	III	 12.69119	 [75]	
Anaplastic	Ependymoma,	Spine,	WHO	grade	III	 12.68655	 [75]	
	Anaplastic	Ependymoma,	Supratentorial-RELA,	WHO	grade	III	 12.84834	 [75]	
	Anaplastic	Ependymoma,	Supratentorial-YAP,	WHO	grade	III	 12.96476	 [75]	
Anaplastic	Ganglioglioma																			 32.70641	 [75]	
	Anaplastic	Oligodendroglioma																							 21.65347	 [75]	
Anaplastic	Pleomorphic	Xanthoastrocytoma																	 12.74161	 [75]	
Angiocentric	Glioma																		 2.022847	 [101],	
[105]	
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Astroblastoma																																								 2.991548	 [101]	
Astrocytoma,	WHO	grade	II,	IDH-Mutated																 5.494821	 [123]	
Astrocytoma,	WHO	grade	II,	IDH-wild	type							 5.429927	 [123]	
Atypical	Choroid	Plexus	Papilloma,	WHO	grade	II				 13.01322	 [31]	
Atypical	Rhabdoid	Tumour											 57.92757	 [75]	
Central	Neurocytoma																											 1.996661	 [75]	
Cerebellar	Liponeurocytoma,	WHO	grade	II														 3.792935	 [75]	
Choroid	Glioma	Of	The	Third	Ventricle										 0.0199971	 [101]	
Choroid	Plexus	Carcinoma																											 49.33664	 [31]	
Choroid	Plexus	Papilloma										 1.900278	 [31]	
Desmoplastic	Infantile	Astrocytoma,	WHO	grade	I									 1.999507	 [101]	
Desmoplastic	Infantile	Ganglioglioma						 3.064397	 [101]	
Diffuse	Leptomeningeal	Glioneuronal	Tumour			 0.5009569	 [99]	
Diffuse	Midline	Glioma,	WHO	grade	IV											 15.76368	 [11]	,[120]	
Diffuse	Oligodendroglioma,	WHO	grade	II							 5.172283	 [11]	
Dysembryoplastic	Neuroepithelial	Tumor							 1.962428	 [101]	
Dysplastic	Cerebellar	Gangliocytoma,	WHO	grade	I							 5.052819	 [75]	
Ependymoma,	Posterior	Fossa	A,	WHO	grade	II		 1.084873	 [75]	
Ependymoma,	Posterior	Fossa	B,	WHO	grade	II					 1.115519	 [75]	
Ependymoma,	Spine,	WHO	grade	II							 1.113177	 [75]	
Ependymoma,	Supratentorial-YAP,	WHO	grade	II		 1.139871	 [75]	
Ependymoma,	Supratentorial,	RELA,	WHO	grade	II			 1.107576	 [75]	
Extraventricular	Neurocytoma							 8.069866	 [91]	
Gangliocytoma,	WHO	grade	I	 2.001002	 [75]	
Ganglioglioma										 1.793866	 [75]	
Glioblastoma,	IDH-mutated																													 38.69587	 [122]	
Glioblastoma,	IDH-wild	type											 39.00361	 [75]	
Medulloblastoma,	non-WNT/non-SHH,	WHO	grade	IV	 36.01142	 [75]	
Medulloblastoma,	SHH	Class,	WHO	grade	IV						 28.6244	 [75]	
Medulloblastoma,	WNT	Group,	WHO	grade	IV							 19.73859	 [75]	
Meningioma,WHO	grade	I	 5.600289	 [75]	
Myxopapillary	Ependymoma							 0.9929882	 [77]	
Paraganglioma																												 2.714961	 [75]	
Pilocytic	Astrocytoma													 5.226825	 [101]	
Pilomyxoid	Astrocytoma																 5.203091	 [75],	[120]	
Pleomorphic	Xanthoastrocytoma,	WHO	grade	II	 6.022234	 [81]	
Rosette-forming	Glioneuronal	Tumors,	WHO	grade	I	 4.18537	 [129]	
Schwannoma,	WHO	grade	I	 2.488276	 [75]	
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Solitary	Fibrous	Tumour/Hemangiopericytoma	Grade	I	 4.684723	 [75]	
Subependymal	Giant	Cell	Astrocytoma,	WHO	grade	I	 2.875666	 [117]	
Subependymoma	 6.117688	 [33],	[67]	
	
One	major	limitation	of	“La	Tabla”	was	the	lack	of	probabilities	in	the	given	data	within	
some	articles.	As	a	result,	it	was	decided	to	transform	the	words	“always”,	“frequently”,	
“usually”,	“often”,	“sometimes”,	“occasionally”,	“seldom”,	“rarely”	and	“never	or	N/A”	in	to	
probabilities:	100%,	90%,	80%,	70%,	50%,	40%,	20%,	10%	and	0%,	respectively.	
	 The	second	limitation	that	was	noticed	during	the	completion	of	“La	Tabla”	was	the	
controversial	data	found	within	different	sources.	For	example,	in	Table	2.,	the	mean	age	of	the	
Atypical	Rhabdoid	Tumour	was	found	to	be	2	years	following	the	2007	WHO	Classification	of	
Tumors	of	the	Central	Nervous	System,	and	23	years	following	the	CBTRUS	data	base.	This	
problem	was	solved	by	calculating	the	weighted	average	between	both	sources.	In	this	case,	
the	result	was	equal	to	8.161617.	
2. R	code.	
Once	“La	Tabla”	was	completed,	each	tumor	type	was	coded	with	a	program	called	R	studio,	
which	is	an	open	source	software	program	mostly	used	for	statistical	analysis	and	developed	by	
S	language	(Tutorialspoint,	2020).		
	 	This	interface	was	used	in	order	to	create	a	database	with	individual	files	of	each	tumor	
type,	that	include	the	information	collected	from	the	Excel	table.	For	that,	different	functions	
were	created	depending	on	the	type	of	information	and	were	added	into	a	data	frame.	A	data	
frame	is	a	two-dimensional	array	structure	in	which	each	column	contains	values	of	one	
variable	and	each	row	contains	one	set	of	values	from	each	column.	The	data	can	be	either	
numerical	or	a	character	type	(Tutorialspoint,	2020).	An	example	of	a	numeric	variable	could	be	
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age,	for	example	the	mean	age	for	glioblastoma	is	61.3	(WHO,	2016).	General	site	is	an	example	
of	a	categorical	variable	since	brainstem	and	frontal	lobe	do	not	account	for	numbers.	In	order	
to	link	the	number	of	probabilities	of	developing	each	tumor	in	a	certain	brain	region,	a	
function	was	created.			
	
Figure	3.	Function	created	with	Rstudio	in	order	to	match	the	probabilities	within	each	region	of	
the	brain	where	this	type	of	glioblastoma	can	be	found.	For	example,	forty	percent	of	the	
glioblastomas	have	the	frontal	lobe	involved.	
	
	 For	the	gender	ratio,	it	was	decided	to	arrange	the	value	1	to	females	and	the	value	0	to	
males.		The	rest	of	variables	like	low	cellularity,	infiltrative	diffuse	and	EGFR	amplification	were	
coded	in	the	same	way.	Similar	functions	to	figure	3	were	created	in	which	the	percentage	
originally	found	in	“La	Tabla”	was	placed	to	set	certain	probabilities.		
	
Figure	4.	The	probability	of	finding	MGMT	in	glioblastomas	is	of	45%,	therefore,	there	are	55%	
of	probability	that	MGMT	will	not	be	found	within	glioblastomas.			
		
	 Ki67	was	coded	in	a	similar	way	than	the	variable	age.	Since	both	variables	are	
numerical,	the	mean	as	well	as	the	standard	deviation	were	included.		
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Figure	5.	Function	created	for	the	numerical	variable	ki67	that	included	the	mean	and	the	
standard	deviation	found	from	literature.	In	this	case	the	mean	accounts	for	my_mean	and	it	is	
equal	to	38.7	and	the	standard	deviation	accounts	for	my_sd	and	it	is	equal	to	7.19.	
	
	 Each	diagnosis	was	integrated	in	to	the	data	frame	with	the	diagnosis_function.		
The	following	figure	represents	an	example	of	the	function	created	for	diagnosis:	
	
Figure	6.	Diagnosis_function	was	created	in	order	to	add	the	type	of	diagnosis	in	to	each	tumor	
type	data	frame.	This	example	is	adding	Glioblastoma	as	the	final	diagnosis	in	to	the	data	
frame.	
	
Finally,	each	tumor	type	was	individually	saved	in	to	the	working	directory	in	two	formats:	.R	
and	.csv.	This	was	done	using	the	saveRDS	as	well	as	the	write.csv	functions.		
	
Figure	7.	This	is	an	example	of	how	the	glioblastoma	data	frame	was	saved	within	the	computer	
using	the	saveRDS	and	write.csv	functions.	
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	 Some	diagnosis,	including	glioblastomas,	share	direct	and	indirect	relationships	with	IHC	
and	molecular	data.		These	correlations	had	to	be	coded	in	a	different	way.	Figure	8,	shows	an	
example	of	how	IDH	mutation	is	related	with	ATRX	loss.	In	this	example,	if	glioblastoma	
accounts	for	positive	IDH	mutation,	there	will	be	an	85%	of	probabilities	that	ATRX	loss	will	be	
positive	as	well.	The	same	coding	process	was	repeated	with	EGFR	amplification.	
Finally,	all	the	coded	gliomas	were	merged	in	to	a	csv.	data	table	that	will	be	used	in	the	next	
steps	
Figure	8.	Relationship	between	IDH	mutation	and	ATRX	loss	in	glioblastoma.	
	
3. Model	Generated	
XGBoost	is	a	machine	learning	algorithm	that	implements	decision	trees	designed	for	speed	
and	performance	on	tabular	datasets	on	classification	and	regression	predictive	modeling	
problems	(Brownlee,	2019).	It	is	a	software	library	that	can	be	downloaded	and	installed	on	R	
studio	and	implements	the	gradient	boosting	decision	tree	algorithm	(which	produces	
predicting	models).	It	is	used	in	a	wide	range	of	computing	environments	like	parallelization	of	
tree	construction,	distributed	computing	in	order	to	train	long	models	using	clustered	machines	
and	caching	optimization	(Brownlee,2019).	
	 18	
C5.0	algorithm	performs	decision	trees	using	entropy	(indicates	how	incorporated	the	class	
values	are)	for	measuring	purity.	The	number	zero,	0,	will	indicated	that	the	sample	is	
homogeneous	or	completely	mixed.	The	number	one,	1,	applies	when	the	sample	is	completely	
separated	or	heterogeneous	(Yobero,	2018).		
The	algorithm	random	forest	gives	an	approach	in	which	each	observation	is	fitted	into	
every	decision	tree	created.	The	most	common	outcome	for	each	observation	is	used	as	the	
final	input.	Also,	a	new	observation	is	included	into	each	tree	and	it	takes	the	greater	number	of	
votes	for	each	classification	model	(R,	2020).	
	 In	order	to	select	the	most	relevant	features	within	the	brain	tumor	data	set,	the	Boruta	
algorithm	was	applied.	This	algorithm	duplicates	and	shuffles	the	values	in	each	column.	To	
ensure	the	accuracy	of	these	features,	Boruta	trained	the	random	forest	classifier	in	order	to	
validate	the	importance	of	the	feature	by	comparing	it	with	random	shuffled	copies	(Pathack,	
2018).	After	this	process,	the	Boruta	algorithm	selected	the	most	relevant	features:	mostly	
clinical	parameters	(age,	ki67,	gender,	tumor	location)	and	data	on	histological	architecture	
(endothelial	proliferation,	cellularity	type	and	etc.).	However,	it	was	decided	to	only	include	
clinical	data	and	ki67	to	the	shiny	app	to	formulate	a	test	example.	The	accuracy	of	the	RF	
model	on	data	from	“La	Tabla”	managed	to	reach	~	60%	in	the	absence	of	IHC,	histology	and	
molecular	data.	However,	in	order	to	increase	the	accuracy	of	the	model	on	data	obtained	from	
patients	at	OSU	we	had	to	add	additional	features	on	distinct	histological	architecture	to	the	
model.	Using	19	features	in	total	our	model	managed	to	predict	the	diagnosis	of	100	OSU	
patients	with	84%	accuracy	and	“La	Tabla”	data	(94%)	in	the	absence	of	molecular	and	IHC	
features	(p53,	ATRX,	IDH	status	and	etc.)		
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Figure	9.	Random	Forest	model	showing	84%	of	accuracy	using	19	features	over	100	OSU	
patients.			
																																																															
Figure	10.	Random	Forest	shows	a	94%	accuracy	when	predicting	diagnosis	with	data	extracted	
from	“La	Tabla”.	
	
Although	XGBoost	and	C5.0	algorithms	proved	to	be	less	accurate	using	same	features	
as	the	Random	Forest	algorithm,	they	could	still	predict	the	diagnosis	on	real	patient	dataset	
with	moderate	accuracy	-	78%	and	72%	respectively	in	the	absence	of	IHC	and	molecular	data.		
4. Shiny	app.	
Shiny	App	is	a	package	within	R	studio	that	provides	the	opportunity	of	creating	interactive	
web	applications.	In	order	to	create	a	functional	Shiny	App,	it	is	important	to	understand	how	it	
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is	organized.	Each	Shiny	App	has	two	parts:	UI,	or	user	interface,	and	the	server.	The	UI	is	HTML	
that	you	use	while	constructing	Shiny	functions,	it	shows	the	user	how	the	layout	of	the	web	is	
arranged.	The	server	part	is	used	to	make	the	app	interactive	for	the	user.	All	Shiny	Apps	have	
the	same	template.	In	order	to	build	Shiny	Apps,	a	template	is	created	that	will	be	composed	of	
the	package	“shiny”	as	well	as	an	empty	UI	and	server	 	
Figure	11.	Template	for	a	Shiny	App	
	
	 For	our	Shiny	App,	the	package	“randomForest”	was	downloaded	since	in	order	to	make	
predictions,	the	model	Random	Forest	is	required	to	be	fitted	in	to	the	app.	The	R	file	with	all	
the	gliomas	coded	as	well	as	the	Random	Forest	model	file	were	imported	to	the	Shiny	App	
using	the	function	readRDS.	Since	the	variables	general	and	specific	site	are	categorical,	they	
were	switched	to	factor	so	they	could	be	incuded	in	to	the	data	frame.	
Figure	12.	Code	used	for	Glioma	Modelling	App	for	importing	models	and	downloaded	
packages.	
	
	 The	inputs	are	functions	placed	by	the	user	in	order	to	create	values	or	interactions.	
They	are	coded	within	the	fluidpage	()	function.	In	this	case,	it	was	decided	to	include	gender,	
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age,	ki67,	general	and	specific	site	with	different	types	of	inputs.	For	that,	this	is	the	code	that	it	
was	used:		
	
															
Figure	13.	Glioma	Modelling	App	code	for	the	UI	interface.	
	
In	Figure	13,	it	is	noticeable	that	there	were	used	three	different	types	of	inputs:	
sliderInput,	radioButtons,	selectInput	and	a	submitButton	that	will	update	the	information	
placed	on	the	inputs	when	clicked.	It	was	decided	to	use	different	inputs	because	the	
information	that	these	inputs	carry	are	different.	For	example,	age	represents	a	number	while	
general	site	represents	multiple	places	within	the	brain.	Therefore,	we	considered	it	
appropriate	to	do	it	this	manner.	
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Figure	14.	Different	inputs	for	the	Glioma	Modelling	App.	
	
	 The	server	part	requires	to	fit	the	model	within	the	function.	For	that,	a	data	frame	was	
created	in	order	to	link	the	inputs	with	the	variables	coded	within	the	glioma	file.	An	example	
that	can	be	observed	in	Figure	5,	it	is	that	“General.site”	is	how	this	variable	was	named	in	the	
glioma	file	and	it	is	equal	to	“input$gsite”	which	is	making	reactive	the	id	input	gsite	(which	it	is	
observed	in	Figure	3).	Therefore,	once	we	choose	a	general	anatomical	sites	in	the	input,	this	
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will	pick	the	information	from	the	glioma	file	and	will	react	with	the	inputs	to	show	the	selected	
information.		
After	the	data	frame	was	created,	the	prediction	of	the	randomForest	model	was	set	up	
giving	place	to	a	bar	plot	that	will	only	include	the	top	five	diagnosis	with	the	highest	
probabilities.	For	that,	the	barplot()	as	well	as	the	predict()	functions	were	used.		
	
Figure	15.	Server	function	for	the	Glioma	Modelling	App.	
	
	 The	only	output	implicit	within	the	server	function	is	called	“distPlot”	and	it	is	linked	to	a	
bar	plot.	For	making	a	Shiny	App	reactive,	it	is	necessary	to	include	the	name	of	the	output	(in	
this	case	is	distPlot()	within	the	main	panel.	
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Figure	16.	Creating	reactivity	in	the	Glioma	Modelling	App.	
	
	 Once	both	of	the	parts	were	filled	(the	UI	and	the	server),	the	application	was	ran	and	
this	was	the	result:	
Figure	17.	Completed	app	for	Glioma	Modelling	Project.	
	 The	theme	that	it	is	usually	used	for	a	regular	Shinny	App	was	switched	in	to	the	
“superhero”	shiny	theme	in	order	to	give	the	web	page	a	different	look	compared	to	regular	
Shiny	Apps.	A	limitation	was	experienced	during	this	method	since	the	diagnosis	under	each	bar	
plot	are	extremely	small,	it	was	decided	to	create	a	legend	with	the	legend()	function	in	order	
to	clarify	the	possible	diagnosis.		
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Results	and	Discussion	
Glioma	Modelling	Project	was	originally	created	in	order	to	simplify	and	avoid	additive	
expenses	of	some	laboratory	processes	that	some	hospitals	do	not	have.	In	this	way,	third	
world	countries	would	not	have	the	means	to	amplify	their	laboratories;	pathologists	would	just	
need	a	few	of	not	expensive	medical	proves	required	to	fill	the	parameters	within	the	shiny	app	
to	obtain	the	probability	of	the	five	tumors	with	most	possibilities	of	being	diagnosed	for	a	
specific	patient.		
	 Since	the	most	updated	version	of	The	World	Health	Organization	has	around	200	
different	types	of	tumors,	it	was	decided	to	select	the	53	most	common	tumor	diagnoses	from	
both	adult	and	pediatric	types.	This	decision	was	made	because	the	lack	of	information	in	
literature	and	academic	articles	about	some	tumor	diagnosis.	Therefore,	the	first	limitation	that	
was	experienced	during	this	project,	was	the	absence	of	information	about	some	very	specific	
tumor	types.	
	 Along	with	this	limitation,	it	was	decided	to	dismiss	some	categories	of	“La	Tabla”	based	
on	the	Boruta	algorithm,	which	was	used	in	order	to	select	the	most	relevant	features	for	our	
study.These	features	account	for	clinical	and	histological	architecture.	Even	though	the	Boruta	
algorithm	selected	more	categories	as	a	shadow	features	(features	with	higher	Z-score),	it	was	
decided	to	only	include	clinical	data	which	included	gender,	age,	general	and	specific	sites,	as	
well	as	ki67	because	it	predicted	diagnosis	with	an	accuracy	of	60%	with	the	random	forest	
algorithm.	
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	 Another	major	limitation	of	this	study	was	the	failed	accuracy	of	diagnosing	some	types	
of	brain	tumors.	This	is	because	the	random	forest	algorithm	only	has	60%	of	accuracy.		An	
example	of	this	would	be	when	the	pediatric	tumor	Pleomorphic	Xanthoastrocytoma	should	be	
diagnosed	when	the	parameters	selected	are:	five	for	age,	seven	for	ki67,	and	the	locations	are	
posterior	fossa	and	infratentorial.	However,	the	type	of	tumor	that	was	diagnosed	following	
these	parameters	was	Diffuse	Midline	Glioma,	WHO	grade	IV	with	more	than	a	70%	of	
probability.	This	is	a	pediatric	tumor	as	well	and	it	usually	has	a	low	ki67,	but	it	is	not	commonly	
found	within	the	posterior	fossa.	Thus,	this	is	an	example	in	which	the	shiny	app	is	not	accurate	
enough.		
	
Figure	18.	Shiny	app	showing	an	inaccurate	diagnosis.		
	
	 There	was	a	study	made	in	September	of	2016	named	“An	Automatic	Classification	of	
Brain	Tumors	through	MRI	Using	Support	Vector	Machine”	that	distinguished	between	benign	
and	malignant	tumors	with	an	accuracy	of	98.9%	using	an	algorithm	called	Support	Vector	
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Machine.	This	algorithm	was	used	in	order	to	recognize	large	tumors	in	MRI’s	from	the	
surrounding	tissues	of	the	brain	while	compared	to	normal	brain	images	(Alfonse	et	al,	2016).		
The	study	results	are	relevant	to	the	Glioma	Modelling	Project	in	order	to	contemplate	
different	approaches	to	get	the	same	results	while	using	MRI	images.	Also,	the	algorithm	SVM,	
which	is	classified	as	a	supervised	model,	could	be	used	as	a	tool	in	order	to	train	our	glioma	
data	to	observe	features	that	the	algorithm	includes.	It	also	observes	which	features	it	excludes	
and	the	accuracy	percentage	of	the	prediction.		
	 There	is	another	recent	study	called	“MethPed:	an	R	package	for	the	identification	of	
pediatric	brain	tumor	subtypes”	that	uses	the	random	forest	algorithm	in	order	to	predict	
pediatric	brain	tumors.	The	prediction	was	done	by	using	DNA	methylation	parameters.	The	R	
package	predicts	five	groups	of	brain	tumors:	glioblastomas,	medulloblastomas,	diffuse	
intrinstic	pontine	gliomas,	ependymomas	and	embryonal	tumors	with	multilayered	rosettes.	
Diagnosis	that	do	not	fit	any	of	these	categories	will	be	determined	as	inconclusive	(Ahamed	et	
al,	2016).	This	study	resulted	very	interesting	since	the	same	algorithm	was	performed,	
however,	this	study	only	predicted	a	small	group	of	brain	tumors	excluding	adult	cases	and	did	
not	give	any	information	about	the	accuracy	of	the	predictions	that	the	package	made.	
Therefore,	the	lack	of	official	results	makes	this	study	not	reliable	even	if	the	method	that	was	
used	to	create	the	predictions	was	the	same	in	both	studies.		
	 For	future	directions,	I	would	suggest	to	increase	the	accuracy	of	the	prediction	of	
tumor	diagnosis	in	order	to	avoid	the	wrong	diagnosis	of	some	brain	tumors.	This	could	be	
solved	by	the	addition	of	molecular	as	well	as	histochemical	data	in	to	the	random	forest	
model.	After	that,	the	addition	of	these	new	features	in	to	the	shiny	app.	If	the	random	forest	
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does	not	increase	its	accuracy	by	adding	molecular	and	histochemical	data,	other	algorithms	
like	support	vector	machine	could	be	tested	in	our	model.	Also,	the	addition	of	more	tumor	
types	in	to	the	shiny	app	could	provide	neuropathologists	the	certainty	of	not	excluding	some	
possible	diagnosis.	
Our	team	is	currently	using	OSU	real	patient	data	to	compare	the	real	results	with	the	
predicted	results	given	by	the	shiny	app.		
Once	the	accuracy	it	is	increased	enough	that	the	website	could	be	considered	as	
credible	and	reliable,	I	believe	that	the	promotion	of	the	shiny	app	would	be	an	excellent	idea.	
This	project	could	be	promoted	through	social	and	professional	media.	Since	the	main	goal	of	
this	project	it	always	has	been	to	extend	the	idea	of	using	artificial	intelligence	to	diagnose	
brain	tumors	in	order	to	make	possible	this	kind	of	diagnosis	without	using	expensive	
laboratory	techniques,	I	believe	that	a	lot	of	hospitals	around	the	world	could	potentially	be	
interested	on	acquiring	this	tool.	For	that,	I	would	suggest	to	offer	this	tool	worldwide	for	free.	
Further	on,	this	project	could	also	be	used	as	a	study	tool	for	neuropathologist’s	and	
neuro-oncologist’s	students.	Since	all	the	predictions	were	done	based	on	decision	trees;	the	
same	method	can	be	developed	for	future	neurology	students	in	order	to	provide	them	an	idea	
of	which	data	a	tumor	is	more	likely	to	have.		
The	findings	of	this	study	can	be	understood	as	the	creation	of	a	free	webpage	that	in	a	
future	will	be	a	worldwide	open	resource	for	doctors	as	well	as	for	medical	students	that	are	
interested	on	neuropathology.	Also,	the	eradication	of	highly	costly	medical	techniques	saving	
the	patients	some	money	up.	Therefore,	more	patients	could	afford	the	diagnosis	and	
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treatment	of	brain	tumors.	Thus,	once	this	tool	is	fully	developed,	the	Glioma	Modelling	Project	
could	help	the	world	saving	more	human	lives.		
	
Glossary:	
	 Sensitivity:	measures	how	often	a	test	correctly	generates	a	positive	result	for	people	
who	have	the	condition	that	is	being	tested	for.	For	example,	a	test	that	is	highly	sensitive	will	
flag	almost	everyone	who	has	the	disease	and	not	generate	many	false	negative	results	(Health	
News	Review).	
	 Specificity:	measures	a	test’s	ability	to	correctly	generate	a	negative	result	for	people	
who	do	not	have	the	condition	that	is	being	tested	for.	One	example	is	that	a	high	specificity	
test	will	correctly	rule	out	almost	everyone	who	does	not	have	the	disease	and	will	not	
generate	many	false	positive	results	(Health	News	Review).	
	 Accuracy:	refers	to	the	correctness	of	a	single	measurement.	It	is	determined	by	
comparing	the	measurement	against	the	true	or	accepted	value.	An	accurate	measurement	is	
close	to	the	true	value.	For	example,	hitting	the	center	of	a	bullseye	(Helmenstine,	2018).	
	 Positive	Predictive	Value	(PPV):	The	likelihood	that	an	individual	with	a	positive	test	
result	truly	has	the	particular	gene	and/or	disease	in	question	(NCI	Dictionary	of	Cancer	Terms).	
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